Phase 2 Hearing Loss Trial, Recruiting (NCT06249919)

Phase 2 Hearing Loss Trial, Recruiting NCT06249919 Sponsor: Neuracle Science Co., LTD. Condition: Hearing Loss

Printed from Voxsanity (voxsanity.com.au) — NCT06249919 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hearing Loss

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Part A:

Healthy volunteers (people without significant health conditions)

Part B:

People who have sudden hearing loss in one ear only (of unknown cause), where the hearing loss measures greater than 45dB on a hearing test, and the other ear has near-normal hearing (less than 30dB hearing loss)
People who have completed a standard treatment recognised by the trial doctor within 30 days of their symptoms starting, and are able to attend the randomisation visit within 35 days of symptoms starting
People who, in the treating doctor's opinion, have received an adequate course of steroid tablets or injections for approximately two weeks
People who have received a combination treatment of approximately two weeks of steroid tablets or injections together with steroid injections directly into the ear

Who may not be able to join:

People who have other ear-related or wider health conditions (confirm with trial site for specific conditions this covers)
People who have a growth or abnormality affecting the hearing nerve (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Joseph Park, M.D., Neuracle Science

Phone: +82269490409

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06249919

Sponsor: Neuracle Science Co., LTD.

Phase: Phase 2

Status: Recruiting

Condition: Hearing Loss

Trial contact: +82269490409

More information: https://clinicaltrials.gov/study/NCT06249919

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Part A:

Healthy volunteers (people without significant health conditions)

Part B:

People who have sudden hearing loss in one ear only (of unknown cause), where the hearing loss measures greater than 45dB on a hearing test, and the other ear has near-normal hearing (less than 30dB hearing loss)
People who have completed a standard treatment recognised by the trial doctor within 30 days of their symptoms starting, and are able to attend the randomisation visit within 35 days of symptoms starting
People who, in the treating doctor's opinion, have received an adequate course of steroid tablets or injections for approximately two weeks
People who have received a combination treatment of approximately two weeks of steroid tablets or injections together with steroid injections directly into the ear

Who may not be able to join:

People who have other ear-related or wider health conditions (confirm with trial site for specific conditions this covers)
People who have a growth or abnormality affecting the hearing nerve (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Neuracle Science Co., LTD.

Registry

ClinicalTrials.gov

Start date

19 January 2024

Est. completion

31 May 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Phase 1b part: Change from Baseline in Safety Profiles; Phase 2a part: Changes from Baseline in Safety Profiles

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov